CCL2 and diabetes mellitus: Previous studies have revealed that HMGB1 inhibitor GA treatment protects against kidney lesions induced by diabetes, which is related to the reduced expression of TNF-α, 1L-6, IL-1β, MCP-1, and ICAM-1 in the kidney[23].